The role of long intergenic non-coding RNA for kinase activation (LINK-A) as an oncogene in non-small cell lung carcinoma.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 02 2021
Historique:
received: 08 04 2020
accepted: 20 01 2021
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 15 12 2021
Statut: epublish

Résumé

The oncogenic role of long intergenic non-coding RNA for kinase activation (LINK-A) has been appraised in triple-negative breast cancer. However, the molecular function of LINK-A is still unclear in most cancers including lung cancer. The present study aimed to evaluate the impact of down-regulation of LINK-A in A549 and Calu-3 cell lines as cellular models of non-small cell lung carcinoma (NSCLC). We used the RNA interference system to knock down LINK-A. LINK-A expression was significantly reduced by siRNA transfection in A549 and Calu-3 cell lines. LINK-A down-regulation significantly reduced cell viability, colony-forming ability and cell migration, as measured by MTT, colony formation and invasion assays. Finally, cell cycle analysis and Annexin-V/7AAD staining indicated that apoptosis was influenced by LINK-A silencing. Taken together, LINK-A can be proposed as an oncogene in NSCLC.

Identifiants

pubmed: 33602983
doi: 10.1038/s41598-021-82892-z
pii: 10.1038/s41598-021-82892-z
pmc: PMC7892821
doi:

Substances chimiques

LINK-A long non-coding RNA, human 0
RNA, Long Noncoding 0
RNA, Small Interfering 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4210

Références

J Biol Chem. 2002 Dec 6;277(49):47014-21
pubmed: 12354771
Anatol J Cardiol. 2018 Aug;20(2):100-109
pubmed: 30088484
Lung. 2016 Aug;194(4):637-46
pubmed: 27166634
Oncol Lett. 2019 Sep;18(3):3049-3057
pubmed: 31404323
Immunol Lett. 2013 Sep-Oct;155(1-2):36-9
pubmed: 24095849
Breast Cancer Res. 2018 Oct 1;20(1):117
pubmed: 30285805
Med Sci Monit. 2019 Mar 26;25:2221-2227
pubmed: 30912527
Cancer Res. 2011 Jan 1;71(1):3-7
pubmed: 21199792
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Int J Mol Sci. 2012;13(2):1951-2011
pubmed: 22408433
PET Clin. 2018 Jan;13(1):1-10
pubmed: 29157380
J Clin Oncol. 2012 Apr 1;30(10):1137-9
pubmed: 22355057
Exp Mol Pathol. 2020 Jun;114:104411
pubmed: 32112788
Oncol Rep. 2017 Sep;38(3):1525-1532
pubmed: 28714007
Biomed Res Int. 2013;2013:746858
pubmed: 24171172
BMC Cancer. 2019 Mar 12;19(1):222
pubmed: 30866866
Database (Oxford). 2013 Oct 31;2013:bat074
pubmed: 24178989
Cancer Res. 2002 Jun 15;62(12):3373-6
pubmed: 12067977
Oncologist. 2004;9 Suppl 1:2-10
pubmed: 15178810
Br J Cancer. 2004 Aug 31;91(5):954-8
pubmed: 15328513
Curr Opin Genet Dev. 2017 Oct;46:170-178
pubmed: 28843809
Blood. 2008 Apr 1;111(7):3322-30
pubmed: 18362212
Hum Antibodies. 2020;28(3):227-232
pubmed: 32333582
Cancer Res. 2003 Jun 15;63(12):3403-12
pubmed: 12810677
Hepatology. 2011 Sep 2;54(3):910-9
pubmed: 21674552
Nat Cell Biol. 2016 Feb;18(2):213-24
pubmed: 26751287
Nat Genet. 2016 Jan;48(1):44-52
pubmed: 26595768
Breast Cancer Res Treat. 2013 Aug;140(3):505-17
pubmed: 23925655
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Biochem J. 2000 Mar 15;346 Pt 3:603-10
pubmed: 10698685
Oncotarget. 2016 Jun 21;7(25):37773-37789
pubmed: 27191981
Br J Nurs. 2013 Sep 12-25;22(17):S15-6, S18, S20-2
pubmed: 24067269
Nat Cell Biol. 2017 Mar;19(3):238-251
pubmed: 28218907
Cancer Res. 2003 Oct 15;63(20):6651-7
pubmed: 14583458
Int J Oncol. 2012 Oct;41(4):1337-46
pubmed: 22825629
Oncol Rep. 2011 Apr;25(4):929-35
pubmed: 21308352
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2009 Sep;4(9):1094-103
pubmed: 19687765
Gastric Cancer. 2018 Jul;21(4):632-642
pubmed: 29204860
Cell Death Dis. 2019 Feb 21;10(3):177
pubmed: 30792387
Blood. 2002 Nov 15;100(10):3767-75
pubmed: 12393646
Cell. 2008 Apr 4;133(1):66-77
pubmed: 18394990
J Cell Physiol. 2012 Feb;227(2):514-24
pubmed: 21503885
Oncogene. 2008 Oct 27;27(50):6398-406
pubmed: 18955968
Mol Cancer. 2011 Apr 13;10:38
pubmed: 21489289

Auteurs

Parichehr Maleki (P)

Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

Seyed Javad Mowla (SJ)

Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Mohammad Taheri (M)

Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Soudeh Ghafouri-Fard (S)

Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Jamshid Raheb (J)

Department of Molecular Medicine, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran. Jam@nigeb.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH